Evidence map›Paper›PMID 37821853›Full record

ArticleBMC infectious diseases2023

Risk factors and titers of COVID-19 infection in a longitudinal statewide seroepidemiology cohort.

Elizabeth T Rogawski McQuade, Lea Becker, Suzanne E Stroup, Fauzia Khan, Bhruga Shah, John Brush, Gay Goldsmith, Rebecca Mullin, Danielle Guilliams, Christopher deFilippi and 6 more

Abstract read
In one paragraph

Article in BMC infectious diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Elizabeth T Rogawski McQuadeDivision of Infectious Diseases and International Health, University of Virginia, Charlottesville, VA, USA.
Lea BeckerDivision of Infectious Diseases and International Health, University of Virginia, Charlottesville, VA, USA.
Suzanne E StroupDivision of Infectious Diseases and International Health, University of Virginia, Charlottesville, VA, USA.
Fauzia KhanResearch & Clinical Trial Analytics Team, University of Virginia, Charlottesville, VA, USA.
Bhruga ShahInova Heart and Vascular Institute, Inova Health System, Falls Church, VA, USA.
John BrushOffice of Clinical Research, Sentara Healthcare, Norfolk, VA, USA.
Gay GoldsmithOffice of Clinical Research, Sentara Healthcare, Norfolk, VA, USA.
Rebecca MullinDivision of Infectious Diseases, Virginia Commonwealth University, Richmond, VA, USA.
Danielle GuilliamsCarilion Clinic, Roanoke, VA, USA.
Christopher deFilippiInova Heart and Vascular Institute, Inova Health System, Falls Church, VA, USA.
Kathleen BarackmanOffice of Clinical Research, Sentara Healthcare, Norfolk, VA, USA.
Andrea B MohrCarilion Clinic, Roanoke, VA, USA.
Francis FarrellCarilion Clinic, Roanoke, VA, USA.
Gonzalo BearmanDivision of Infectious Diseases, Virginia Commonwealth University, Richmond, VA, USA.
Lilian PeakeVirginia Department of Health, Richmond, VA, USA.
Eric R HouptDivision of Infectious Diseases and International Health, University of Virginia, Charlottesville, VA, USA. Erh6k@virginia.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundVirginia is a large state in the USA, yet it remains unclear what percentage of the population has had natural COVID-19 infection and whether risk factors for infection have changed over time.

methodsUsing a longitudinal cohort, from December 2021-July 2022 we performed follow up serology and a questionnaire on 784 individuals from across Virginia who had previously participated in a statewide COVID-19 seroepidemiology study in 2020. Children were also invited to participate and an additional 62 children also completed the study. Serology was performed using Roche nucleocapsid and spike serological assays.

resultsThe majority of participants were white (78.6%), over 50 years old (60.9%), and reported having received COVID-19 vaccine (93.4%). 28.6% had evidence of prior COVID-19 infection (nucleocapsid positive). Reweighted by region, age, and sex to match the Virginia census data, the seroprevalence of nucleocapsid antibodies was estimated to be 30.6% (95% CI: 24.7, 36.6). We estimated that 25-53% of COVID-19 infections were asymptomatic. Infection rates were lower in individuals > 60 years old and were higher in Blacks and Hispanics. Infection rates were also higher in those without health insurance, in those with greater numbers of household children, and in those that reported a close contact or having undergone quarantine for COVID-19. Participants from Southwest Virginia had lower seropositivity (16.2%, 95% CI 6.5, 26.0) than other geographic regions. Boosted vaccinees had lower infection rates than non-boosted vaccinees. Frequenting indoor bars was a risk factor for infection, while frequently wearing an N95 mask was protective, though the estimates of association were imprecise. Infection rates were higher in children than adults (56.5% vs. 28.6%). Infection in the parent was a risk factor for child infection. Spike antibody levels declined with time since last vaccination, particularly in those that were vaccinated but not previously infected. Neutralizing antibody positivity was high (97-99%) for wild type, alpha, beta, gamma, delta, and omicron variants. Neutralizing antibody levels were higher in the follow-up survey compared to the first survey in 2020 and among individuals with evidence of natural infection compared to those without.

conclusionsIn this longitudinal statewide cohort we observed a lower-than-expected COVID-19 infection rate as of August 2022. Boosted vaccinees had lower infection rates. Children had higher infection rates and infections tracked within households. Previously identified demographic risk factors for infection tended to persist. Even after the omicron peak, a large number of Virginians remain uninfected with COVID-19, underscoring the need for ongoing vaccination strategies.

Indexed as

Antibodies, NeutralizingCOVID-19AdultAntibodies, ViralChildCOVID-19 VaccinesHumansLongitudinal StudiesMiddle AgedRisk FactorsSARS-CoV-2Seroepidemiologic StudiesVirginiaAntibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesCOVID-19NucleocapsidRisk factorsSARS-CoV-2SeroepidemiologySpikeVaccine

Identifiers

PMID37821853
PMCPMC10565985

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.